Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H16N2O4S2 |
| Molecular Weight | 268.354 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCSSCC[C@H](N)C(O)=O)C(O)=O
InChI
InChIKey=ZTVZLYBCZNMWCF-WDSKDSINSA-N
InChI=1S/C8H16N2O4S2/c9-5(7(11)12)1-3-15-16-4-2-6(10)8(13)14/h5-6H,1-4,9-10H2,(H,11,12)(H,13,14)/t5-,6-/m0/s1
| Molecular Formula | C8H16N2O4S2 |
| Molecular Weight | 268.354 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Importance of the trans-sulfuration pathway in cancer prevention and promotion. | 2007-07 |
|
| Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. | 2007-05 |
|
| Influence of combined methionine synthase (MTR 2756A > G) and methylenetetrahydrofolate reductase (MTHFR 677C > T) polymorphisms to plasma homocysteine levels in Korean patients with ischemic stroke. | 2007-04-30 |
|
| A rationale for cystine supplementation in severe homocystinuria. | 2007-02 |
|
| Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. | 2007-01 |
|
| Thermolabile methylenetetrahydrofolate reductase C677T polymorphism and homocysteine are risk factors for coronary artery disease in Moroccan population. | 2007 |
|
| Differential effects of endogenous cysteine analogs on peripheral thermal nociception in intact rats. | 2006-11 |
|
| Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. | 2006-09-26 |
|
| The screening power of methylenetetrahydrofolate reductase C677T polymorphism versus plasma homocysteine concentration in patients with stenosis of the internal carotid artery. | 2006-09-25 |
|
| A new method for determination of plasma homocystine by isotope dilution and electrospray tandem mass spectrometry. | 2006-09-14 |
|
| Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. | 2006-07 |
|
| California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. | 2006-06-30 |
|
| Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation). | 2006-04 |
|
| Homocysteine transport by human aortic endothelial cells: identification and properties of import systems. | 2006-02-15 |
|
| Homocyst(e)ine and stroke. | 2006-02 |
|
| Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. | 2006-01-23 |
|
| Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. | 2006-01-11 |
|
| Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. | 2005-11-07 |
|
| Workgroup report: Biomonitoring study design, interpretation, and communication--lessons learned and path forward. | 2005-11 |
|
| Fibrinogen, homocyst(e)ine, and C-reactive protein concentrations relative to sex and socioeconomic status in British young people. | 2005-10-29 |
|
| Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. | 2005-04 |
|
| Aleurone flour increases red-cell folate and lowers plasma homocyst(e)ine substantially in man. | 2005-03 |
|
| Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. | 2005-02 |
|
| Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. | 2005-02 |
|
| Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. | 2005 |
|
| Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. | 2005 |
|
| Inflammation causes tissue-specific depletion of vitamin B6. | 2005 |
|
| Is Hyperhomocyst(e)inemia a humoral predictor of coronary heart disease? | 2005 |
|
| High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. | 2004-11 |
|
| Hyperhomocyst(e)inemia is an important risk factor for vascular disease in subjects with high-molecular weight apo(a) isoforms. | 2004-10-16 |
|
| The C677T methylenetetrahydrofolate reductase variant and third trimester obstetrical complications in women with unexplained elevations of maternal serum alpha-fetoprotein. | 2004-09-07 |
|
| [A case of young adult presenting with cerebral infarction caused by homocystinuria]. | 2004-09 |
|
| Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. | 2004-05-10 |
|
| Methylenetetrahydrofolate reductase 677 C-->T polymorphism and plasma folate in relation to pre-eclampsia risk among Peruvian women. | 2004-05 |
|
| Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. | 2004-05 |
|
| [Prevention of dementia (including Alzheimer's disease)]. | 2004-05 |
|
| The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men. | 2004-04 |
|
| Folic acid improves endothelial function in children and adolescents with type 1 diabetes. | 2004-04 |
|
| L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. | 2004-03-01 |
|
| Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. | 2004-02-17 |
|
| Comparing the ESA HPLC total homocysteine assay with electrochemical detection to the CDC in-house HPLC assay with fluorescence detection. | 2004-02 |
|
| Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. | 2003-08-26 |
|
| Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the Third National Health and Nutrition Examination Survey. | 2003-08-05 |
|
| Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. | 2003-06 |
|
| Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. | 2003-06 |
|
| Association between homocyst(e)ine levels and risk of vascular events. | 2003-03 |
|
| Study of total homocyst(e)ine levels in type 2 diabetic patients with silent brain infarction. | 2003 |
|
| 2 minute non-invasive screening for cardio-vascular diseases: relative limitation of C-Reactive Protein compared with more sensitive L-Homocystine as cardio-vascular risk factors; safe and effective treatment using the selective drug uptake enhancement method. | 2003 |
|
| Established and recently identified coronary heart disease risk factors in young people: the influence of physical activity and physical fitness. | 2003 |
|
| Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go? | 2001 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:26 GMT 2025
by
admin
on
Mon Mar 31 17:50:26 GMT 2025
|
| Record UNII |
804AS222UE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
55879-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
30051-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
26809-4
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
20646-6
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
2431-5
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
54302-5
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
25441-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
13399-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
26882-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
27352-4
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
26999-3
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
16711-4
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
CFR |
21 CFR 862.1377
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
15135-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
2429-9
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
22660-5
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
22715-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
2430-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
22673-8
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
25929-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
56682-8
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
22707-4
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
14053-3
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
13759-6
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
38486-7
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
44720-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
13372-8
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
25928-3
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
44378-8
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
6884-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
||
|
LOINC |
15143-1
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
626-72-2
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
207-323-8
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
ALTERNATIVE | |||
|
210-962-5
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
804AS222UE
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
m6043
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
Homocystine
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
DTXSID001019905
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
D006711
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
17485
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY | |||
|
439579
Created by
admin on Mon Mar 31 17:50:26 GMT 2025 , Edited by admin on Mon Mar 31 17:50:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |